Skip To Main Content
Mariel Savelius on Muck Rack

Mariel Savelius

As seen in: BioRxiv, Cell Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mariel

Contact Mariel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Complex I drives glutamine-dependent TCA cycle to support viability of MYC high breast cancer cells

|
By Johanna M. Anttila, Mariel Savelius, Daniel Nicorici, Juhi Somani, Pauliina M. Munne, Aino Peura, July Aung, Ryan Awadhpersad, Ellisiv Nyhamar, Bina Prajapati, Prson Gautam, Mika J. Välimäki, Topi A. Tervonen, Raman Devarajan, Minna Mutka, Panu E. Kovanen, Laura Niinikoski, Tuomo J. Meretoja, Johanna Mattson, Päivi Heikkilä, Krister Wennerberg, Marie Arsenian-Henriksson, Jukka Westermarck, Tero Aittokallio, Andrei Goga, Christopher Jackson, Anni Nieminen, Juha Klefström, Antti O. Hiltunen, Martina Peltonen, Hanna Ala-Hongisto
| Cell Reports Verified
Results MYC activity signatures have been used, for example, to define subtypes of breast cancer with the highest MYC activity for trials with MYC pathway-directed drugs,3,23 to predict clinical outcomes among MYC-associated cancers,24,25 and more recently, to define metabolic alterations that associate with MYChigh areas within mouse and human tumors.26 To define which published transcriptional MYC activity signatures correlate best with high levels of MYC protein expression, we determined...
Open in Who Shared Issue with article?

Complex I Drives Glutamine-Dependent TCA Cycle to Support Viability of MYChigh Breast Cancer Cells

|
By Johanna M. Anttila, Juhi Somani, Mariel Savelius, Daniel Nicorici
| BioRxiv
Abstract In many cancers, stably elevated MYC levels drive persistent and concerted activation of cell growth promoting anabolic programs and the cell cycle in ways that are distinct from normal cells. Therefore, synthetic-lethal strategies to target MYC reprograming of these pathways may identify new selective anticancer therapies for the treatment of MYChigh tumors. Here, we identify enhanced mitochondrial respiration as a hallmark of MYC overexpressing cancer cells.
Open in Who Shared Issue with article?
See all 2 articles